A randomised clinical trial investigating the monoclonal anti-IL-1β antibody canakinumab in post-myocardial infarction patients demonstrated a reduction in C-reactive protein (CRP) levels by up to 41%, along with a decreased incidence of major cardiovascular events (nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death) [7,8]. Here, CRP is linked to myocardial infarction.